Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00462566
Other study ID # CDHA004
Secondary ID
Status Completed
Phase N/A
First received April 17, 2007
Last updated October 17, 2016
Start date October 2005
Est. completion date July 2010

Study information

Verified date June 2016
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The objective is to determine if motor cortex stimulation works for the following conditions:

1. Deafferentation facial pain,

2. Upper extremity complex regional pain syndrome (CRPS) and

3. Brachial plexus avulsion or phantom limb pain.

Each of these groups of 6 patients (total of 18) will be studied independently and all patients will be implanted with a motor cortex stimulation system. They will be randomised to either a regular or low stimulation setting in the two arms of the study. Each arm will last 3 months.


Description:

This is a prospective, blinded randomized crossover study comparing two stimulation paradigms in three different groups of patients receiving motor cortex stimulation. The aim of this study is to examine the effectiveness of this modality in a controlled blinded manner, which has not been done in previous studies. There are two primary purposes of this study. The first is to compare two different stimulation paradigms: "high" level stimulation (i.e. stimulator activated 'on' for 10 minutes, 'off' for 2 hours; presumed therapeutic dose); versus "low" stimulation ('on' for 1 minute, 'off' for 6 hours; presumed subtherapeutic dose), in a prospective blinded crossover study design.

The second purpose of this study, is to examine the outcome of MCS in three different pain groups. These are:

1. Unilateral upper extremity neuropathic pain such as brachial plexus avulsion, stump pain or phantom limb pain

2. Neuropathic deafferentation facial pain

3. Upper extremity complex regional pain syndrome (CRPS)

Measurements of the effects of motor cortex stimulation will include a visual analogue scale (VAS) of perceived pain, the McGill Pain Questionnaire, SF-36 quality of life questionnaire, Beck Depression Inventory-II, the standard 7-point patient global impression of change (PGIC), medications log (verified by pharmacy records) and an employment status questionnaire. Adverse events will be recorded at each visit.

Table 1:

Visit Study Week Standard Care 0a 1b 12c 24d 1a 2e 3f 4g F/Uh Clinic Visit X X X X X X Consent X Surgery X X X Program MCS X X X X X X VAS X X X X X X X SF-36 X X X X X X X Medications Log X X X X Employment Status X X X X McGill Pain X X X X X X X Beck Depression II X X X X Global impression of change X X

1. Screening visit in consideration of MCS

2. Immediate post-op visit, randomization to high or low settings

3. 12 week crossover point

4. Final study visit, MCS programmed at 'best' settings

5. Trial period of MCS, lasting for 1 to 2 weeks

6. Clinic visit to determine efficacy of MCS and removal of temporary external system.

7. Permanent implantation of MCS, if trial was successful

8. Follow-up as required.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

1. Diagnosis in one of the following three categories:

- Unilateral upper extremity neuropathic pain such as phantom limb pain, stump pain or brachial plexus avulsion

- Neuropathic deafferentation facial pain

- Upper extremity complex regional pain syndrome (CRPS)

2. Pain is refractory to conservative methods (e.g. medications, regional blocks) as reviewed by a chronic pain clinical physician

3. Patient is considered a good candidate for neurosurgery, i.e. no other medical problems that would preclude surgery

4. Patients who are willing to provide informed consent.

Exclusion Criteria:

1. Patients who are not considered medically fit for neurosurgery.

2. Patients who have not exhausted conservative methods of pain control, prior to considering motor cortex stimulation.

3. Patients who are not able to provide informed consent.

4. Patients unable to have magnetic resonance imaging (MRI).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Intervention

Device:
motor cortex stimulation


Locations

Country Name City State
Canada Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia

Sponsors (2)

Lead Sponsor Collaborator
Nova Scotia Health Authority Dalhousie University

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Radic JA, Beauprie I, Chiasson P, Kiss ZH, Brownstone RM. Motor Cortex Stimulation for Neuropathic Pain: A Randomized Cross-over Trial. Can J Neurol Sci. 2015 Nov;42(6):401-9. doi: 10.1017/cjn.2015.292. Epub 2015 Sep 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analog scale 1 month preop, at 12 and 24 weeks postop No
Primary SF-36 1 month preop, at 12 and 24 weeks postop No
Primary McGill Pain questionnaire 1 month preop, at 12 and 24 weeks postop No
Primary Beck II depression 1 month preop, at 12 and 24 weeks postop No
Primary Global impression of change at 12 and 24 weeks postop No
Primary Medications log 1 month preop, at 12 and 24 weeks postop No
Primary Employment status 1 month preop, at 12 and 24 weeks postop No
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2